Literature DB >> 33168395

Impaired intestinal barrier function in type 2 diabetic patients measured by serum LPS, Zonulin, and IFABP.

Jie-Hao Yuan1, Qing-Sheng Xie2, Guang-Cheng Chen3, Chu-Lin Huang4, Tao Yu3, Qi-Kui Chen5, Jie-Yao Li6.   

Abstract

INTRODUCTION: The epithelial tight junctions of intestine were impaired in murine model of type 2 diabetes mellitus (T2DM). The aim of this work was to investigate the alteration of intestinal barrier in T2DM patients.
METHODS: 90 patients with T2DM and 28 healthy controls were recruited. Serum lipopolysaccharide (LPS), Zonulin, and intestinal fatty acid binding protein (IFABP) were measured by ELISA, based on which a derived permeability risk score (PRS) was calculated. Subgroup analyses were conducted based on the glycemic control (HbA1c < 7%, or HbA1c ≥ 7%), the amount of chronic diabetic complications, and the use of aspirin at the time.
RESULTS: Serum LPS, Zonulin, and IFABP, and PRS of T2DM group were significantly higher than those of the control group (p < 0.05 for all). Serum LPS and PRS was higher in T2DM patients with poor glycemic control (both p < 0.05). Patients with more chronic complications of diabetes had higher serum LPS and IFABP, and PRS (all p < 0.05). No differences were found in these serum markers between T2DM patients being treated with aspirin or not.
CONCLUSIONS: Intestinal barrier function was impaired in T2DM patients. Poor glycemic control and more chronic complications of diabetes were associated with worse intestinal barrier function. Treatment with aspirin did not aggravate the impairment of intestinal barrier in T2DM patients.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IFABP; Intestinal barrier function; LPS; Type 2 diabetes mellitus; Zonulin

Mesh:

Substances:

Year:  2020        PMID: 33168395     DOI: 10.1016/j.jdiacomp.2020.107766

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  8 in total

1.  Is type 2 diabetes mellitus another intercellular junction-related disorder?

Authors:  Carla B Collares-Buzato; Carolina Pf Carvalho
Journal:  Exp Biol Med (Maywood)       Date:  2022-04-23

2.  Chlorogenic Acid-Induced Gut Microbiota Improves Metabolic Endotoxemia.

Authors:  Xiaolin Ye; Yang Liu; Jiajin Hu; Yanyan Gao; Yanan Ma; Deliang Wen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-16       Impact factor: 5.555

3.  Electroacupuncture at Lower He-Sea and Front-Mu Acupoints Ameliorates Insulin Resistance in Type 2 Diabetes Mellitus by Regulating the Intestinal Flora and Gut Barrier.

Authors:  Haili Wang; Xinhua Chen; Chunhai Chen; Ting Pan; Mengyuan Li; Lin Yao; Xuefeng Li; Qi Lu; Hongfeng Wang; Zhaohui Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2022-07-30       Impact factor: 3.249

Review 4.  Research Progress on the Therapeutic Effect of Polysaccharides on Non-Alcoholic Fatty Liver Disease through the Regulation of the Gut-Liver Axis.

Authors:  Xiang Chen; Menghan Liu; Jun Tang; Ning Wang; Yibin Feng; Haotian Ma
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

5.  Bifidobacterium longum 070103 Fermented Milk Improve Glucose and Lipid Metabolism Disorders by Regulating Gut Microbiota in Mice.

Authors:  Tong Jiang; Ying Li; Longyan Li; Tingting Liang; Mingzhu Du; Lingshuang Yang; Juan Yang; Runshi Yang; Hui Zhao; Moutong Chen; Yu Ding; Jumei Zhang; Juan Wang; Xinqiang Xie; Qingping Wu
Journal:  Nutrients       Date:  2022-09-29       Impact factor: 6.706

6.  Exploring the Link between Leaky-Gut-Related Markers and Metabolic Health in a Large Dutch Adult Population.

Authors:  Hiroyuki Hoshiko; Edith J M Feskens; Els Oosterink; Renata M C Ariens; Jurriaan J Mes; Nicole J W de Wit
Journal:  Metabolites       Date:  2021-12-16

7.  A narrative review of the role of gastrointestinal dysbiosis in the pathogenesis of polycystic ovary syndrome.

Authors:  Jim Parker; Claire O'Brien; Jason Hawrelak
Journal:  Obstet Gynecol Sci       Date:  2021-12-28

8.  Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

Authors:  Olivier Deckmyn; Thierry Poynard; Pierre Bedossa; Valérie Paradis; Valentina Peta; Raluca Pais; Vlad Ratziu; Dominique Thabut; Angelique Brzustowski; Jean-François Gautier; Patrice Cacoub; Dominique Valla
Journal:  Biomedicines       Date:  2022-03-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.